Welcome to our dedicated page for Iradimed news (Ticker: IRMD), a resource for investors and traders seeking the latest updates and insights on Iradimed stock.
Iradimed Corporation (IRMD) provides essential medical technologies for MRI environments through its innovative devices. This news hub offers investors and healthcare professionals timely updates on product developments, financial performance, and operational milestones.
Access official press releases and verified news about IRMD's MRI-compatible infusion systems, patient monitoring solutions, and regulatory achievements. Stay informed about quarterly earnings, partnership announcements, and clinical validation studies that demonstrate the company's market leadership.
Key updates include FDA clearances, international expansion efforts, and technological enhancements to the company's non-magnetic device ecosystem. Content is organized chronologically showcase IRMD's progress in improving MRI safety standards while maintaining financial transparency.
Bookmark this page for direct access to primary source materials from Iradimed Corporation. Check regularly for updates on innovations addressing critical needs in diagnostic imaging and patient care during magnetic resonance procedures.
IRADIMED CORPORATION (NASDAQ: IRMD), a leader in MRI-compatible patient monitoring and infusion systems, announced key changes to its Board of Directors. Anthony Vuoto, who served as director since 2016, has retired effective August 27, 2025. The company has appointed Joe Kiani, founder of Masimo Corporation, as his replacement effective September 2, 2025.
Kiani, a distinguished medical technology innovator with over 500 patents or patent applications, will serve on the Board's audit committee and as chairman of the compensation committee. He brings extensive experience from his roles as former Chairman and CEO of Masimo (1989-2024), current CEO of Willow Laboratories and Like Minded Labs, and board member of CDX Medical Technologies.
IRADIMED CORPORATION (NASDAQ: IRMD), a specialized manufacturer of MRI-compatible patient monitoring and infusion systems, has announced its participation in the upcoming Wells Fargo 2025 Healthcare Conference. The conference will take place from September 3-5, 2025, in Boston, Massachusetts.
The company's leadership, including President and CEO Roger Susi and CFO Jack Glenn, will conduct one-on-one meetings with investors on September 4, 2025. This invitation-only event brings together healthcare industry leaders and institutional investors to explore sector trends and opportunities.
Iradimed Corporation (NASDAQ:IRMD) reported record Q2 2025 financial results, with revenue reaching $20.4 million, a 14% increase year-over-year. The company achieved GAAP diluted EPS of $0.45 and non-GAAP diluted EPS of $0.49, marking increases of 18% and 17% respectively.
The company declared a quarterly dividend of $0.17 per share, payable on August 28, 2025. Iradimed raised its full-year 2025 guidance, now expecting revenue between $80.0-82.5 million and GAAP diluted EPS of $1.60-1.70.
Q2 highlights include a strong 78% gross profit margin, record backlog for pump and monitor products, and completion of a new facility in July 2025. For Q3 2025, the company projects revenue of $20.5-20.9 million with GAAP diluted EPS of $0.41-0.45.
Iradimed Corporation (NASDAQ: IRMD) has scheduled its second quarter 2025 financial results conference call for August 1, 2025. The company will release its financial results before the market opens, followed by a management-hosted conference call at 11:00 a.m. Eastern Time.
Participants can join the call by registering through the provided link, after which they will receive dial-in details and a unique pin. The call will also be available via live webcast on the company's investor relations website, with a recording accessible afterward.
Iradimed Corporation (NASDAQ: IRMD) has received FDA 510(k) clearance for its MRidium® 3870 IV Infusion Pump System, a next-generation MRI-compatible infusion pump. The device maintains Iradimed's unique position as the world's only provider of non-magnetic MRI infusion pumps since 2005. The new system features a non-magnetic ultrasonic pump motor, non-interfering RF emissions, and an enhanced touchscreen interface.
Key features include the ability to operate independently or as a four-channel system, and a modern drug library solution supporting multiple patient care areas. The company plans to begin deployment to select healthcare facilities in Q4 2025, with full commercial distribution ramping throughout 2026.
IRADIMED (NASDAQ: IRMD) reported strong Q1 2025 financial results with record revenue of $19.5 million, up 11% year-over-year. The company achieved GAAP diluted EPS of $0.37 and non-GAAP diluted EPS of $0.42, representing increases of 16% and 17% respectively. The Board declared a quarterly dividend of $0.17 per share, payable on May 30, 2025.
The company maintained its full-year 2025 guidance, expecting revenue between $78.0-82.0 million and GAAP diluted EPS of $1.55-1.65. For Q2 2025, IRADIMED projects revenue of $19.7-19.9 million. Domestic sales represented 82% of total revenue, and gross profit margin remained steady at 76.1%. The company's new manufacturing facility is on track for completion in July 2025, with approximately $3.0 million in remaining construction costs.
IRADIMED (NASDAQ: IRMD) has announced its upcoming first quarter 2025 financial results release and conference call schedule. The company will release its Q1 2025 financial results before market opening on Monday, May 5, 2025. Management will host a conference call at 9:00 a.m. Eastern Time on the same day to discuss the results and address questions.
Interested participants can register for the conference call through a provided link. Upon registration, they will receive a dial-in number, unique pin, and instructions. The call will also be available via live webcast on the company's investor relations website, with a recording made available afterward.
IRADIMED (NASDAQ: IRMD) has scheduled its first quarter 2025 financial results announcement for Friday, May 5, 2025, before market opening. The company will host a conference call at 9:00 a.m. Eastern Time on the same day to discuss the results and address questions.
Interested participants can register for the conference call through a provided link, after which they will receive dial-in details and a unique pin. The call will also be available via live webcast on the company's investor relations website, with a recording accessible afterward.
IRADIMED (NASDAQ: IRMD) has announced its participation in the upcoming 37th Annual Roth Conference. The event will take place on March 17 and 18, 2025, at the Laguna Cliffs Marriott in Dana Point, CA.
The company will be represented by CFO Jack Glenn and CCO Jeff Chiprin, who will conduct one-on-one meetings with investors during the conference.
IRADIMED (NASDAQ: IRMD) reported record Q4 2024 revenue of $19.4 million, up 11% year-over-year, marking its fourteenth consecutive quarter of revenue growth. The company achieved Q4 GAAP diluted EPS of $0.40 and non-GAAP diluted EPS of $0.44.
For full-year 2024, revenue reached $73.2 million, a 12% increase from 2023, with GAAP diluted EPS of $1.50 and non-GAAP diluted EPS of $1.66. The company increased its quarterly dividend to $0.17 per share from $0.15.
Looking ahead to 2025, IRADIMED projects revenue between $78.0-82.0 million, with GAAP diluted EPS of $1.55-1.65 and non-GAAP diluted EPS of $1.71-1.81. Q1 2025 guidance indicates revenue of $19.2-19.4 million with GAAP diluted EPS of $0.35-0.39.
FAQ
What is the current stock price of Iradimed (IRMD)?
What is the market cap of Iradimed (IRMD)?
